AdaptHealth (AHCO) Scheduled to Post Quarterly Earnings on Tuesday

AdaptHealth (NASDAQ:AHCO) will release its earnings data before the market opens on Tuesday, November 5th. Analysts expect AdaptHealth to post earnings of $0.17 per share for the quarter. AdaptHealth has set its FY 2024 guidance at EPS.Persons that are interested in participating in the company’s earnings conference call can do so using this link.

AdaptHealth (NASDAQ:AHCO) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.06). AdaptHealth had a negative net margin of 21.20% and a positive return on equity of 9.58%. The firm had revenue of $805.98 million for the quarter, compared to analyst estimates of $802.62 million. During the same quarter in the previous year, the company earned $0.16 EPS. The company’s quarterly revenue was up 1.6% compared to the same quarter last year. On average, analysts expect AdaptHealth to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

AdaptHealth Trading Up 1.6 %

Shares of NASDAQ AHCO opened at $10.82 on Tuesday. The stock’s 50 day moving average price is $10.77 and its two-hundred day moving average price is $10.41. AdaptHealth has a 52-week low of $6.37 and a 52-week high of $11.90. The stock has a market capitalization of $1.45 billion, a P/E ratio of -2.05, a PEG ratio of 1.60 and a beta of 1.10. The company has a quick ratio of 0.94, a current ratio of 1.15 and a debt-to-equity ratio of 1.38.

Wall Street Analysts Forecast Growth

Separately, Royal Bank of Canada reaffirmed an “outperform” rating and set a $13.00 target price on shares of AdaptHealth in a report on Monday, August 12th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, AdaptHealth presently has a consensus rating of “Hold” and a consensus target price of $10.70.

Insider Activity

In other news, Director David Solomon Williams III sold 4,000 shares of the company’s stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $11.26, for a total transaction of $45,040.00. Following the completion of the transaction, the director now directly owns 36,899 shares of the company’s stock, valued at approximately $415,482.74. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, COO Shaw Rietkerk sold 25,000 shares of the stock in a transaction that occurred on Friday, September 20th. The stock was sold at an average price of $11.24, for a total value of $281,000.00. Following the completion of the transaction, the chief operating officer now directly owns 212,611 shares of the company’s stock, valued at $2,389,747.64. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director David Solomon Williams III sold 4,000 shares of the stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $11.26, for a total value of $45,040.00. Following the completion of the transaction, the director now directly owns 36,899 shares of the company’s stock, valued at $415,482.74. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 4.43% of the company’s stock.

AdaptHealth Company Profile

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.